knowledge -WSS

knowledge

author：knowledge 2025-08-12 09:08:25 - browse：6871

Doctor holding a clipboard. -- health coverage from STAT — Adobe

The momentum around weight loss drugs is about to get even bigger in the wake of Novo Nordisk’s announcement that its semaglutide drug Wegovy cut the risk of cardiovascular disease by 20% in its large SELECT trial.

The full results of the study, funded by Novo, will be presented at the American Heart Association meeting in November. Doctors and researchers say they expect the findings to have a big impact on how clinicians approach the treatment of both obesity and cardiovascular disease, as well as increase the likelihood that prescriptions for obesity drugs will be covered by insurance.

But experts who spoke with STAT also cautioned that the long-term safety and efficacy of Wegovy and other weight loss drugs remain unknown. The SELECT study has yet to be peer-reviewed, and not enough information is yet available to make independent assessments of the results.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Flagship Pioneering startup Sonata Therapeutics lays off 21

hotspot

leisure time

WSS

New study raises questions about niacin and heart health

Medicare to pay more for cardiac rehab in hospital outpatient clinics

The struggle to figure out which patients 'deserve' Wegovy

Neurocrine congenital adrenal hyperplasia trial succeeds

Neurocrine congenital adrenal hyperplasia trial succeeds

Hospitals are piloting generative AI tools as regulators play catch

leisure time

knowledge

focus

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

In 'major milestone,' FDA approves first cell therapy for solid tumors

State Dept. review finds Biden bears some blame for Afghanistan failures

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Medicare details structure of new drug price negotiation program

Surprise medical billing ban raises prices elsewhere

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Akili changes sales model for its ADHD video game treatment

Guidelines to prevent youth baseball injuries need more muscle

Congress may force more Covid

knowledge

Neurocrine congenital adrenal hyperplasia trial succeeds

The struggle to figure out which patients 'deserve' Wegovy

FDA panel to weigh safety of artificial wombs for preterm births

Flagship Pioneering startup Sonata Therapeutics lays off 21

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Grad students accuse University of California of wage theft

hotspot

hotspot

leisure time

explore